VigiPallia : Résultats

Background: Limited evidence exists on the impact of palliative rehabilitation during systemic treatment of advanced cancer.
Aim: To explore the experiences and perceptions of patients and healthcare professionals on the feasibility and acceptability of palliative rehabilitation during advanced lung cancer treatment.
Design: Qualitative design using individual semi-structured interviews transcribed verbatim and analysed thematically.
Setting/participants: Eight patients and six healthcare professionals were recruited from a regional cancer centre in the United Kingdom following completion of a 6-week individualised behaviour change study which combined physical activity and nutritional guidance.
Results: Palliative rehabilitation and study participation were positively viewed by both participants and healthcare professionals. Five themes were identified from patient interviews within an overarching theme of living with and beyond an advanced cancer diagnosis: (1) challenges of living with incurable cancer, (2) personal and altruistic reasons for participating in rehabilitation, (3) applicability of palliative rehabilitation content, (4) barriers and facilitators to adherence and (5) positive impact on self and others. Three themes were identified from healthcare professionals, within an overarching theme of palliative rehabilitation: exploring the concept (1) pre-study-mixed perceptions of palliative rehabilitation, (2) perceived benefits for patients and families and (3) lessons for future research.
Conclusion: Patients described personal benefits associated with setting their own goals for physical activity and dietary intake. Healthcare professionals who initially expressed a negative or indifferent stance towards palliative rehabilitation, displayed a mind-set change and were keen to explore further opportunities to expand the evidence base.

Origine : SAGE Journals

Integrating palliative home care early into standard care of end-stage COPD

SCHEERENS, Charlotte
ASP nv , 2019 , 297 p.

Gabapentin for cough in cancer

RAZZAK, Rab ; WALDFOGEL, Julie M. ; DOBERMAN, Danielle J. ; FELICIANO, Josephine L. ; SMITH, Thomas J.
Journal of pain and palliative care pharmacotherapy, 02/10/2017, vol.31, n°3-4, p. 195-197

Document en ligne

Is in-hospital mortality higher in patients with metastatic lung cancer who received treatment in the last month of life? - a retrospective cohort study

MIERAS, Adinda ; PASMAN, H. Roeline W. ; ONWUTEAKA-PHILIPSEN PROF, Bregje D. ; DINGEMANS, Anne-Marie M. C. ; KOK, Edith V. ; CORNELISSEN, Robin ; JACOBS, Wouter ; VAN DEN BERG, Jan-Willem ; WELLING, Alle ; BOGAARTS, Brigitte A. H. A. ; PRONK, Lemke ; BECKER-COMMISSARIS, Annemarie
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 05/07/2019, Pagination inconnue

Document en ligne

Renal cell carcinoma pseudoprogression with clinical deterioration - to hospice and back

ELIAS, Roy ; KAPUR, Payal ; PEDROSA, Ivan ; BRUGAROLAS, James
Clinical genitourinary cancer, 12/2018, vol.16, n°6, p. 485-488

Document en ligne

Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications

RICCIUTI, Biagio ; DAHLBERG, Suzanne E. ; ADENI, Anika ; SHOLL, Lynette M. ; NISHINO, Mizuki ; AWAD, Mark M.
Journal of clinical oncology, 17/06/2019, Pagination inconnue

Document en ligne

Thème : Médecine.

ANTI INFLAMMATOIRE STEROIDIEN ; DEMARCHE PALLIATIVE ; MALADIE RESPIRATOIRE ; IMMUNOTHERAPIE ; CANCER RESPIRATOIRE

Purpose: Baseline use of corticosteroids is associated with poor outcomes in patients with non-small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition. To approach the question of causation versus correlation for this association, we examined outcomes in patients treated with immunotherapy depending on whether corticosteroids were administered for cancer-related palliative reasons or cancer-unrelated indications.
Patients and methods: Clinical outcomes in patients with NSCLC treated with immunotherapy who received >= 10 mg prednisone were compared with outcomes in patients who received 0 to < 10 mg of prednisone.
RESULTS: Of 650 patients, the 93 patients (14.3%) who received >= 10 mg of prednisone at the time of immunotherapy initiation had shorter median progression-free survival (mPFS) and median overall survival (mOS) times than patients who received 0 to < 10 mg of prednisone (mPFS, 2.0 v 3.4 months, respectively; P = .01; mOS, 4.9 v 11.2 months, respectively; P < .001). When analyzed by reason for corticosteroid administration, mPFS and mOS were significantly shorter only among patients who received >= 10 mg prednisone for palliative indications compared with patients who received >= 10 mg prednisone for cancer-unrelated reasons and with patients receiving 0 to < 10 mg of prednisone (mPFS, 1.4 v 4.6 v 3.4 months, respectively; log-rank P < .001 across the three groups; mOS, 2.2 v 10.7 v 11.2 months, respectively; log-rank P < .001 across the three groups). There was no significant difference in mPFS or mOS in patients receiving >= 10 mg of prednisone for cancer-unrelated indications compared with patients receiving 0 to < 10 mg of prednisone.
CONCLUSION: Although patients with NSCLC treated with >= 10 mg of prednisone at the time of immunotherapy initiation have worse outcomes than patients who received 0 to < 10 mg of prednisone, this difference seems to be driven by a poor-prognosis subgroup of patients who receive corticosteroids for palliative indications.

Origine : PubMed

Patterns of end-of-life oncologic care for stage IV non-small cell lung cancer in the United States

HAQUE, Waqar ; VERMA, Vivek ; BUTLER, E. Brian ; TEH, Bin S.
Anticancer research, 06/2019, vol.39, n°6, p. 3137-3140

Document en ligne

The intensity of hospital care utilization by dutch patients with lung or colorectal cancer in their final months of life

DE MAN, Yvonne ; ATSMA, Femke ; OOSTERVELD-VLUG, Mariska G. ; BROM, Linda ; ONWUTEAKA-PHILIPSEN, Bregje D. ; WESTERT, Gert P. ; GROENEWOUD, A. Stef
Cancer control, 12/2019, vol.26, n°1, p. 1-9

Document en ligne

Ten-year trends of utilization of palliative care services and life-sustaining treatments and hospital costs associated with patients with terminally ill lung cancer in the United States from 2005 to 2014

HWANG, Jinwook ; SHEN, Jay ; KIM, Sun Jung ; CHUN, Sung-Youn ; KIOKA, Mutsumi ; SHERAZ, Faizan ; KIM, Pearl ; BYUN, David ; YOO, Ji Won
The American journal of hospice and palliative care, 23/05/2019, Pagination inconnue

Document en ligne

End-of-life health-care cost of patients with lung cancer - a retrospective study

SOULIOTIS, Kyriakos ; KANI, Chara ; MARIOLI, Androniki ; KAMBOUKOU, Aggeliki ; PRINOU, Aikaterini ; SYRIGOS, Konstantinos ; MARKANTONIS, Sophia
Health services research and managerial epidemiology, 12/2019, vol.6, p. 1-9

Document en ligne

Twenty-eight-day mortality in lung cancer patients with metastasis who initiated mechanical ventilation in the emergency department

SHIN, Sun Hye ; LEE, Hyun ; KANG, Hyung Koo ; PARK, Joo Hyun
Scientific reports, 20/03/2019, vol.9, n°1, p. 1-7

Document en ligne

(1) 2 3 4 ... 9 > »

Actions

##titre_notice##